Nkarta (NASDAQ:NKTX) PT Lowered to $15.00

Nkarta (NASDAQ:NKTX - Get Free Report) had its target price lowered by analysts at Canaccord Genuity Group from $16.00 to $15.00 in a report released on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's price target indicates a potential upside of 140.00% from the stock's current price.

NKTX has been the topic of several other reports. Raymond James reissued an "outperform" rating and set a $16.00 target price (up from $13.00) on shares of Nkarta in a research note on Friday, March 22nd. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 target price on shares of Nkarta in a report on Wednesday, April 10th. HC Wainwright lowered their target price on shares of Nkarta from $22.00 to $20.00 and set a "buy" rating for the company in a report on Friday, March 22nd. Finally, Mizuho lowered their target price on shares of Nkarta from $31.00 to $25.00 and set a "buy" rating for the company in a report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nkarta currently has a consensus rating of "Buy" and a consensus target price of $17.67.

Nkarta Price Performance

NKTX stock traded down $0.05 during trading on Friday, reaching $6.25. 1,951,566 shares of the company were exchanged, compared to its average volume of 1,761,246. The company has a 50-day moving average of $9.79 and a two-hundred day moving average of $7.26. The company has a market capitalization of $308.85 million, a price-to-earnings ratio of -2.63 and a beta of 0.88. Nkarta has a twelve month low of $1.28 and a twelve month high of $16.24.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.05. On average, analysts forecast that Nkarta will post -2.36 EPS for the current year.

Insider Buying and Selling at Nkarta

In other Nkarta news, insider James Trager sold 4,143 shares of Nkarta stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $12.00, for a total transaction of $49,716.00. Following the transaction, the insider now directly owns 149,415 shares of the company's stock, valued at $1,792,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Simeon George acquired 2,000,000 shares of Nkarta stock in a transaction on Wednesday, March 27th. The shares were acquired at an average cost of $10.00 per share, with a total value of $20,000,000.00. Following the transaction, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider James Trager sold 4,143 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $12.00, for a total transaction of $49,716.00. Following the sale, the insider now owns 149,415 shares in the company, valued at approximately $1,792,980. The disclosure for this sale can be found here. 5.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nkarta

A number of hedge funds have recently bought and sold shares of the company. Innovis Asset Management LLC purchased a new stake in Nkarta during the 3rd quarter valued at about $193,000. Bleakley Financial Group LLC purchased a new stake in Nkarta during the 4th quarter valued at about $70,000. Bailard Inc. purchased a new stake in Nkarta during the 4th quarter valued at about $106,000. Acadian Asset Management LLC purchased a new stake in Nkarta during the 3rd quarter valued at about $89,000. Finally, Simplicity Solutions LLC purchased a new stake in Nkarta during the 4th quarter valued at about $70,000. Institutional investors own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.